Ozempic vs Wegovy vs Mounjaro: An Honest Comparison

The question I get most often about GLP-1 medications is some version of "which one is best?" It depends on your situation. But that does not mean all three options are interchangeable. The differences are real, measurable, and worth understanding.

This comparison is based on clinical trial data, FDA labeling, and the current (as of early 2026) pricing and coverage landscape. I will be specific about what the data shows and where the data has gaps.

What Each Drug Actually Is

Ozempic and Wegovy: Same Drug, Different Labels

This is the most common point of confusion. Ozempic and Wegovy both contain semaglutide, manufactured by Novo Nordisk. They are the same molecule injected subcutaneously once per week.

The differences are dosing and FDA-approved indication.

Ozempic is approved for type 2 diabetes management. Its maximum dose is 2.0 mg per week (a 1.0 mg dose is also available). Wegovy is approved for chronic weight management. Its target maintenance dose is 2.4 mg per week, which is 20% higher than Ozempic's maximum.

In practice, many doctors prescribe Ozempic off-label for weight loss. Sometimes this is because it is easier to get covered by insurance (diabetes medications generally have better coverage than weight loss medications). Sometimes it is because Wegovy has been in and out of shortage since its launch.

The practical consequence: someone taking Ozempic at 1.0 mg for weight loss is getting less than half the weight-loss dose studied in the STEP trials. They will still lose some weight, but likely less than someone on Wegovy 2.4 mg. If you are using Ozempic for weight loss and have plateaued, the dose difference may be part of the reason.

Mounjaro and Zepbound: A Different Molecule Entirely

Mounjaro and Zepbound both contain tirzepatide, manufactured by Eli Lilly. Like the Ozempic/Wegovy split, these are the same molecule with different approved indications. Mounjaro is approved for type 2 diabetes. Zepbound is approved for chronic weight management.

Tirzepatide is fundamentally different from semaglutide. Where semaglutide is a GLP-1 receptor agonist only, tirzepatide is a dual GIP/GLP-1 receptor agonist. It activates both the GLP-1 pathway (appetite reduction, slowed gastric emptying, insulin secretion) and the GIP pathway (additional effects on appetite, fat metabolism, and insulin sensitivity).

Whether that dual mechanism explains the better weight loss or whether tirzepatide just happens to be a more potent molecule is still debated. Either way, tirzepatide produces more weight loss in clinical trials.

Head-to-Head Efficacy: What the Data Shows

We do not have a direct randomized trial comparing Wegovy 2.4 mg against Zepbound 15 mg in a weight loss population. That is the comparison everyone wants, and it does not exist yet.

What we do have is the SURPASS-2 trial (published in the NEJM in 2021), which compared tirzepatide against semaglutide 1.0 mg in patients with type 2 diabetes. This is not a perfect comparison because the semaglutide dose was 1.0 mg (the diabetes dose, not the 2.4 mg weight loss dose), but it is the closest head-to-head data available.

At 40 weeks, tirzepatide 15 mg produced 12.4 kg of weight loss versus 6.2 kg with semaglutide 1.0 mg. Tirzepatide at 10 mg produced 11.2 kg. Even tirzepatide at its lowest dose (5 mg) beat semaglutide 1.0 mg: 7.8 kg versus 6.2 kg.

When we compare across trials (understanding that cross-trial comparisons have significant methodological limitations), the picture looks like this:

At the highest tirzepatide dose, more than half of participants lost over 20% of their body weight. With semaglutide, about a third did. For a 250-pound person, that is roughly 37 pounds versus 52 pounds.

A caveat: these are different trials with different patient populations, different sites, and slightly different timeframes. The gold-standard comparison (randomized, double-blind, same patients) is being done in the ongoing SURMOUNT-5 trial, which directly compares tirzepatide 15 mg against semaglutide 2.4 mg. Initial results announced in late 2024 confirmed tirzepatide's superiority, with a roughly 5 percentage point greater weight loss.

Dosing Schedules Compared

All three medications are weekly subcutaneous injections. But their titration schedules differ, and this matters because the ramp-up period determines how long it takes to reach a therapeutic dose and how much time you spend dealing with dose-escalation side effects.

A few practical notes. The Wegovy and Mounjaro/Zepbound titration schedules are designed to be followed as written. Each step gives your body time to adapt before increasing the dose. Rushing this process leads to worse side effects without meaningfully faster weight loss.

Ozempic's titration is somewhat more flexible because it is a diabetes drug where dosing is titrated based on blood sugar response, not weight loss. Many people on Ozempic for weight loss stay at 1.0 mg and never go to 2.0 mg, which means they are getting less than half the dose that was studied for weight loss in the STEP trials.

Not everyone needs the maximum dose. Some people achieve excellent results at lower doses with fewer side effects. Discuss with your prescriber whether the maximum dose is right for you.

Cost Comparison: The Real Numbers

Drug pricing in the US is a mess. List prices, negotiated insurance rates, manufacturer coupons, and compounding pharmacy prices all overlap. Here is my best attempt at what you will actually pay, as of early 2026.

A few things that complicate this picture. Eli Lilly launched LillyDirect in early 2024, letting patients buy single-dose vials of tirzepatide at $549/month directly from the company, bypassing pharmacies and insurance entirely. That undercut the brand-name price by nearly half.

Novo Nordisk has not offered a similar direct-to-consumer program for semaglutide, though manufacturer savings cards can reduce costs for commercially insured patients.

Medicare does not cover weight loss medications. That shuts out a large population of older adults with obesity. The Treat and Reduce Obesity Act has been introduced to change this, but as of early 2026, it has not passed.

Insurance Coverage: The Obstacle Course

Getting insurance to cover a GLP-1 medication for weight loss is often a multi-step process. Here is what it typically involves.

Step 1: Prior authorization. Almost every insurer requires your doctor to submit documentation showing you meet certain criteria, typically a BMI threshold, evidence of weight-related conditions, and documentation of failed lifestyle interventions.

Step 2: Formulary check. Your specific plan may cover Wegovy but not Zepbound, or vice versa. Some plans cover neither for weight loss but cover Ozempic or Mounjaro for diabetes.

Step 3: Step therapy. Some insurers require you to try and fail a less expensive medication first (like phentermine or naltrexone-bupropion) before they will approve a GLP-1.

Step 4: Ongoing documentation. Many insurers require periodic re-authorization, sometimes every 6 or 12 months, with evidence that the medication is working (usually defined as a 5% weight loss threshold).

Many people who would benefit from these medications cannot access them because of cost and coverage barriers. If your insurance denies coverage, ask your doctor about the appeals process. First-level denials are often overturned.

Compounded GLP-1 Medications: The Gray Market

Compounding pharmacies have become a big part of the GLP-1 market. This deserves a direct discussion.

Under the Federal Food, Drug, and Cosmetic Act, compounding pharmacies can produce copies of FDA-approved drugs when those drugs are listed on the FDA Drug Shortage List. Semaglutide was on the shortage list from March 2022 through early 2024. During that period, compounding pharmacies legally produced and sold semaglutide at a fraction of the brand-name price.

As Novo Nordisk ramped up production and the FDA resolved the shortage designation, the legal basis for compounding semaglutide started to disappear. Novo Nordisk filed lawsuits. The FDA issued guidance restricting compounding. Some pharmacies have continued to operate in legal gray areas, arguing various exemptions.

Tirzepatide went through a similar cycle: shortage designation, legal compounding, then resolution of shortage and legal challenges.

If you are considering a compounded version, here is what you should know.

Quality is variable. Brand-name drugs undergo rigorous FDA manufacturing oversight. Compounding pharmacies are regulated by state boards of pharmacy, with varying levels of oversight. Testing by independent labs has found that some compounded semaglutide products contain less active ingredient than labeled, and some have contained impurities. Others have tested accurately. You are relying on the specific pharmacy's quality control.

Legal status is uncertain. What is legal today may not be tomorrow. Several compounding pharmacies have received cease-and-desist letters. If you are on a compounded version and the pharmacy is forced to stop producing it, you need a backup plan.

Dosing may differ. Compounded versions may come in vials that require you to draw up your own injection, rather than pre-filled pens. This introduces the possibility of dosing errors. Make sure you are comfortable with the injection process and have been properly trained.

I am not going to tell you whether compounded GLP-1s are right for you. Brand-name pricing makes compounded versions the only option for many people. Just understand the trade-offs before you start.

Side Effect Comparison

GI side effects are common with all GLP-1 medications, but the rates differ enough to be worth comparing.

Tirzepatide has lower GI side effect rates across the board, despite producing more weight loss. The vomiting gap stands out: 25% versus 12%. If GI tolerance is a concern for you, tirzepatide may be the easier drug to stay on.

Discontinuation rates are similar between the two drugs (roughly 6-7%). Semaglutide causes more GI symptoms, but most people can tolerate them well enough to stay on the drug.

For a more detailed discussion of side effects and management strategies, see our complete guide to GLP-1 side effects.

The Decision Framework

No single medication is "best" for everyone. But the data points toward some reasonably clear recommendations depending on your situation.

What About Oral Semaglutide?

Rybelsus is an oral formulation of semaglutide, currently approved only for type 2 diabetes at doses up to 14 mg daily. It is taken as a pill rather than an injection, which some people prefer.

However, oral semaglutide at the 14 mg dose produces significantly less weight loss than the injectable 2.4 mg dose. Oral bioavailability of semaglutide is only about 1%, meaning most of the pill is destroyed in the GI tract before it gets absorbed. You need a much larger dose orally to achieve the same blood levels.

Novo Nordisk is developing a higher-dose oral semaglutide (25 mg and 50 mg) specifically for weight loss. Phase 3 trials (the OASIS program) showed the 50 mg oral dose produced about 15.1% weight loss at 68 weeks, which is comparable to injectable Wegovy 2.4 mg. An FDA application has been submitted, with potential approval in 2026.

If you hate needles, this might eventually be your best option. But it is not available for weight loss yet.

The Next Generation: What Is Coming

Several next-generation GLP-1 drugs are in late-stage development.

Retatrutide (Eli Lilly) is a triple agonist hitting GLP-1, GIP, and glucagon receptors. Phase 2 data published in the NEJM in 2023 showed up to 24.2% weight loss at 48 weeks. Phase 3 trials are ongoing.

Orforglipron (Eli Lilly) is a non-peptide oral GLP-1 agonist. Unlike Rybelsus (which is a peptide squeezed into a pill), orforglipron is a small molecule with much better oral bioavailability. Phase 2 data showed up to 14.7% weight loss at 36 weeks. Phase 3 trials are underway.

CagriSema (Novo Nordisk) combines semaglutide with cagrilintide (an amylin analog). The REDEFINE program is testing this combination, with early data suggesting weight loss potentially exceeding individual components.

Expect more effective drugs, more delivery options (oral, higher doses), and eventually lower costs as competition increases. But for now, semaglutide and tirzepatide are the options on the table.

Making Your Decision

Talk to your doctor. They know your medical history, your insurance situation, and your goals. What I can tell you from the data: tirzepatide produces more weight loss with fewer GI side effects. Semaglutide has stronger cardiovascular outcomes data. Both work. Neither is cheap.

Whichever medication you choose, the basics still apply. Eat enough protein (our GLP-1 calculator can help you figure out exactly how much). Do resistance training. Stay hydrated. Titrate slowly. Track your progress beyond just the scale.

The medication is a tool. What you do with it is up to you.